Combining Chemistry and Engineering for Hepatocellular Carcinoma: Nano-Scale and Smaller Therapies
Primary liver cancer, or hepatocellular carcinoma (HCC), is a major worldwide cause of death from carcinoma. Most patients are not candidates for surgery and medical therapies, including new immunotherapies, have not shown major improvements since the modest benefit seen with the introduction of sor...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-12-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/12/12/1243 |
| _version_ | 1797544099642867712 |
|---|---|
| author | Danielle L. Stolley Anna Colleen Crouch Aliçan Özkan Erin H. Seeley Elizabeth M. Whitley Marissa Nichole Rylander Erik N. K. Cressman |
| author_facet | Danielle L. Stolley Anna Colleen Crouch Aliçan Özkan Erin H. Seeley Elizabeth M. Whitley Marissa Nichole Rylander Erik N. K. Cressman |
| author_sort | Danielle L. Stolley |
| collection | DOAJ |
| description | Primary liver cancer, or hepatocellular carcinoma (HCC), is a major worldwide cause of death from carcinoma. Most patients are not candidates for surgery and medical therapies, including new immunotherapies, have not shown major improvements since the modest benefit seen with the introduction of sorafenib over a decade ago. Locoregional therapies for intermediate stage disease are not curative but provide some benefit. However, upon close scrutiny, there is still residual disease in most cases. We review the current status for treatment of intermediate stage disease, summarize the literature on correlative histopathology, and discuss emerging methods at micro-, nano-, and pico-scales to improve therapy. These include transarterial hyperthermia methods and thermoembolization, along with microfluidics model systems and new applications of mass spectrometry imaging for label-free analysis of pharmacokinetics and pharmacodynamics. |
| first_indexed | 2024-03-10T13:54:41Z |
| format | Article |
| id | doaj.art-d85903b7de9242089cb0851d0369548f |
| institution | Directory Open Access Journal |
| issn | 1999-4923 |
| language | English |
| last_indexed | 2024-03-10T13:54:41Z |
| publishDate | 2020-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj.art-d85903b7de9242089cb0851d0369548f2023-11-21T01:45:45ZengMDPI AGPharmaceutics1999-49232020-12-011212124310.3390/pharmaceutics12121243Combining Chemistry and Engineering for Hepatocellular Carcinoma: Nano-Scale and Smaller TherapiesDanielle L. Stolley0Anna Colleen Crouch1Aliçan Özkan2Erin H. Seeley3Elizabeth M. Whitley4Marissa Nichole Rylander5Erik N. K. Cressman6Department of Biomedical Engineering, The University of Texas, Austin, TX 78712, USAInterventional Radiology, M.D. Anderson Cancer Center, Houston, TX 77030, USAWyss Institute for Biologically Inspired Engineering at Harvard University, Boston, MA 02115, USADepartment of Chemistry, University of Texas at Austin, Austin, TX 78712, USAInterventional Radiology, M.D. Anderson Cancer Center, Houston, TX 77030, USADepartment of Biomedical Engineering, The University of Texas, Austin, TX 78712, USAInterventional Radiology, M.D. Anderson Cancer Center, Houston, TX 77030, USAPrimary liver cancer, or hepatocellular carcinoma (HCC), is a major worldwide cause of death from carcinoma. Most patients are not candidates for surgery and medical therapies, including new immunotherapies, have not shown major improvements since the modest benefit seen with the introduction of sorafenib over a decade ago. Locoregional therapies for intermediate stage disease are not curative but provide some benefit. However, upon close scrutiny, there is still residual disease in most cases. We review the current status for treatment of intermediate stage disease, summarize the literature on correlative histopathology, and discuss emerging methods at micro-, nano-, and pico-scales to improve therapy. These include transarterial hyperthermia methods and thermoembolization, along with microfluidics model systems and new applications of mass spectrometry imaging for label-free analysis of pharmacokinetics and pharmacodynamics.https://www.mdpi.com/1999-4923/12/12/1243hepatocellular carcinomacirrhosishyperthermiaablationtransarterial chemoembolizationmicrofluidics |
| spellingShingle | Danielle L. Stolley Anna Colleen Crouch Aliçan Özkan Erin H. Seeley Elizabeth M. Whitley Marissa Nichole Rylander Erik N. K. Cressman Combining Chemistry and Engineering for Hepatocellular Carcinoma: Nano-Scale and Smaller Therapies Pharmaceutics hepatocellular carcinoma cirrhosis hyperthermia ablation transarterial chemoembolization microfluidics |
| title | Combining Chemistry and Engineering for Hepatocellular Carcinoma: Nano-Scale and Smaller Therapies |
| title_full | Combining Chemistry and Engineering for Hepatocellular Carcinoma: Nano-Scale and Smaller Therapies |
| title_fullStr | Combining Chemistry and Engineering for Hepatocellular Carcinoma: Nano-Scale and Smaller Therapies |
| title_full_unstemmed | Combining Chemistry and Engineering for Hepatocellular Carcinoma: Nano-Scale and Smaller Therapies |
| title_short | Combining Chemistry and Engineering for Hepatocellular Carcinoma: Nano-Scale and Smaller Therapies |
| title_sort | combining chemistry and engineering for hepatocellular carcinoma nano scale and smaller therapies |
| topic | hepatocellular carcinoma cirrhosis hyperthermia ablation transarterial chemoembolization microfluidics |
| url | https://www.mdpi.com/1999-4923/12/12/1243 |
| work_keys_str_mv | AT daniellelstolley combiningchemistryandengineeringforhepatocellularcarcinomananoscaleandsmallertherapies AT annacolleencrouch combiningchemistryandengineeringforhepatocellularcarcinomananoscaleandsmallertherapies AT alicanozkan combiningchemistryandengineeringforhepatocellularcarcinomananoscaleandsmallertherapies AT erinhseeley combiningchemistryandengineeringforhepatocellularcarcinomananoscaleandsmallertherapies AT elizabethmwhitley combiningchemistryandengineeringforhepatocellularcarcinomananoscaleandsmallertherapies AT marissanicholerylander combiningchemistryandengineeringforhepatocellularcarcinomananoscaleandsmallertherapies AT eriknkcressman combiningchemistryandengineeringforhepatocellularcarcinomananoscaleandsmallertherapies |